CRABP2 and cancer: Approximately half of CRC patients develop CRLM; however, the molecular mechanisms underlying this phenomenon are not fully understood.[2] Here, we identified a dual role for CRABP2—a cytoplasmic‐to‐nuclear transport protein linked with various cancers—in CRC progression and CRLM through its multifaceted and complex interactions in the cytoplasm and nucleus.